Immitra Bio
Scalable In-vivo Gene Editing Platform
- Website
- immitrabio.com
- Total Funding
- $3.0M
- Last Round
- $3.0M Pre-SeedJul 2026
- Rounds
- 1
About
Immitra Bio is developing a novel in-vivo gene editing platform enabling precise, durable, and safe genetic medicine treatments.
Summary
Immitra Bio is a Biotech company. It has raised $3.0M in total across 1 round, most recently a $3.0M Pre-Seed round in Jul 2026. Investors include BackBone Ventures and OCCIDENT.
Tech & App Stack
1 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Jul 2026
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Simtra provides pharmaceutical and biotech clients development and manufacturing services for ste...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
Specialty pharmaceutical company
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/immitra-bio"><img src="https://indexed.vc/api/badge/company/immitra-bio" alt="Immitra Bio on Indexed.vc" width="260" height="76" /></a>